University of California

John M Timmerman

Sherie L Morrison

Kham M Trinh

Alex Vasuthasawat

Reiko King

Patricia Young

In various embodiments methods are provided that involve the use of antibody-interferon (Ab-IFN) fusion proteins to boost the cancer-fighting capacity of adoptive T cell therapies (ACT), including any T cells that are manipulated and grown outside the body, then returned to the patient with the goal of having the infused T cells home to sites of tumor and destroy the cancer in an immunologic attack. Illustrative, but non-limiting, adoptive T cell therapies include chimeric antigen receptor (CAR) T cells, tumor-infiltrating lymphocytes (TILs), virus-specific T cells, and T cell receptor transgenic T cells.

Antibody-interferon fusion proteins for enhancing adoptive T cell therapies for the treatment of cancer

In various embodiments chimeric moieties (constructs) are provided that show significant efficacy against cancers. In certain embodiments the constructs comprise a targeting moiety that specifically binds CSPG4 attached to an interferon or to a mutant interferon. In certain embodiments, the constructs comprise anti-CSPG4 antibody attached to an interferon alpha (IFN-&#x3b1;) or to a mutant interferon alpha or to an interferon beta (IFN-&#x3b2;) or to a nutant interferon beta, or to an interferon gamma (IFN-&#x3b3;) or to a mutant interferon gamma.

Anti-CSPG4 fusions with interferon for the treatment of malignancy

In various embodiments chimeric moieties (constructs) are provided that show significant efficacy against cancers. In certain embodiments the constructs comprise a targeting moiety that specifically binds CSPG4 attached to an interferon or to a mutant interferon. In certain embodiments, the constructs comprise anti-CSPG4 antibody attached to an interferon alpha (IFN-&#x3b1;) or to a mutant interferon alpha or to an interferon beta (IFN-&#x3b2;) or to a mutant interferon beta, or to an interferon gamma (IFN-&#x3b3;) or to a mutant interferon gamma.

The invention relates to methods for making vaccines using linkages that are cleavable under lysosomal processing conditions, and vaccine compositions obtained therefrom. In some embodiments, the vaccines comprise a tumor antigen, an immunogenic carrier and a linker covalently linking the tumor antigen and the immunogenic carrier by a thio ether linkage. Vaccines of preferred embodiments can be used against a cellular proliferative disease that is characterized by the tumor antigen.

Growing community of inventors

Los Angeles, CA, United States of America

John M Timmerman